Oxford Biodynamics Plc logo

Oxford Biodynamics Plc (LMQ)

Market Closed
3 Jun, 20:00
XFRA XFRA
0. 0005
-0.005
-90.91%
- Market Cap
- P/E Ratio
- Div Yield
15,250 Volume
- Eps
0.0055
Previous Close
Add Transaction
Day Range
0.0005 0.0005
Year Range
0.0005 0.017
Want to track LMQ and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

LMQ closed today lower at €0, a decrease of -90.91% from yesterday's close, completing a monthly increase of 0% or €0. Over the past 12 months, LMQ stock lost -75%.
LMQ is not paying dividends to its shareholders.
The last earnings report, released on Feb 26, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 4 different exchanges and in various currencies, with the primary listing on LSE (GBX).

LMQ Chart

Oxford Biodynamics Plc (LMQ) FAQ

What is the stock price today?

The current price is €0.0005.

On which exchange is it traded?

Oxford Biodynamics Plc is listed on XFRA.

What is its stock symbol?

The ticker symbol is LMQ.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has Oxford Biodynamics Plc ever had a stock split?

No, there has never been a stock split.

Oxford Biodynamics Plc Profile

Biotechnology Industry
Healthcare Sector
Iain Gladstone Ross CEO
XFRA Exchange
GB00BD5H8572 ISIN
GB Country
51 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Oxford BioDynamics Plc is a pioneering biotechnology company that plays a crucial role in the discovery and development of biomarkers across a variety of medical and healthcare sectors, with a focus on serving the pharmaceutical and biotechnology industries. Founded in 2007 and based in Oxford, the United Kingdom, the company has made significant inroads into markets primarily in the United States and the United Kingdom. At the core of its operations is EpiSwitch, an innovative proprietary technology platform designed to revolutionize the screening, evaluation, validation, and ongoing monitoring of 3D genomic biomarkers. This technological advantage enables Oxford BioDynamics to offer advanced solutions for diagnosing patients with unprecedented precision.

Products and Services

  • EpiSwitch Prostate Screening Test (PSE)

    This pioneering product represents a significant advancement in prostate cancer screening. The EpiSwitch PSE is designed to improve early detection rates of prostate cancer, thereby potentially improving patient outcomes through early intervention.

  • EpiSwitch CiRT (Checkpoint Inhibitor Response Test)

    A ground-breaking blood test that predicts a patient's therapeutic response to checkpoint inhibitor immunotherapies. This test is crucial for personalizing cancer treatment plans, making sure patients receive the treatments most likely to be effective for their specific condition.

  • EpiSwitch CST (Covid Severity Test)

    An advanced blood test developed for predicting the severity of COVID-19 in adults. This tool is invaluable for medical professionals aiming to tailor treatment strategies based on the predicted severity of the infection in patients, potentially saving lives and optimizing healthcare resources during the pandemic.

  • EpiSwitch Explorer Array Kit

    Offers comprehensive high-resolution 3D genome profiling capabilities. This product is essential for researchers and clinicians who are involved in detailed genomic studies, providing them with the tools needed to explore and understand the complex nature of the genome in three dimensions.

Contact Information

Address: 3140 Rowan Place
Phone: 44 1865 518 910